Sequential use of temsirolimus (TEM) in patients with metastatic renal cell carcinoma (mRCC): Safety and efficacy following failure of receptor tyrosine kinase inhibitor (TKI) treatment.

Trial Profile

Sequential use of temsirolimus (TEM) in patients with metastatic renal cell carcinoma (mRCC): Safety and efficacy following failure of receptor tyrosine kinase inhibitor (TKI) treatment.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Mar 2010

At a glance

  • Drugs Temsirolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Mar 2010 Results were presented at the ASCO 2010 Genitourinary Cancers Symposium.
    • 05 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top